Legend Biotech (LEGN) Income from Continuing Operations (2019 - 2025)
Legend Biotech (LEGN) posted Income from Continuing Operations of 8400000.0 for Q4 2025, up 78.16% quarter-over-quarter from 38457000.0 in Q3 2025, and down 115.36% year-on-year from 54700000.0 in Q4 2024.
Legend Biotech (LEGN) Income from Continuing Operations (2019 - 2025) Analysis & Trends
Legend Biotech (LEGN) has reported Income from Continuing Operations for 7 consecutive years, with 8400000.0 the latest figure, recorded in Q4 2025.
- Income from Continuing Operations for Q4 2025 came in at 8400000.0, down 115.36% year-over-year; the trailing twelve-month figure through Dec 2025 was 268417000.0 (down 92.72% YoY), and the FY2025 annual result was 268400000.0, down 92.82% from the prior year.
- Income from Continuing Operations was 8400000.0 for Q4 2025 at Legend Biotech, up from 38457000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 535350000.0 in Q3 2022 and troughed at 410811000.0 in Q4 2021.
- Average Income from Continuing Operations over 5 years is 55793049.7, with a median of 80063500.0 recorded in 2023.
- The widest YoY moves for Income from Continuing Operations: up 529.13% in 2022, down 32288.91% in 2022.
- Over 5 years, Income from Continuing Operations stood at 410811000.0 in 2021, then soared by 67.0% to 135570000.0 in 2022, then declined by 8.29% to 146813994.0 in 2023, then jumped by 137.26% to 54700000.0 in 2024, then sank by 115.36% to 8400000.0 in 2025.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 8400000.0 in Q4 2025, 38457000.0 in Q3 2025, and 124216000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | 74.00 Mn |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | -14.46 Mn |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 227.36 Mn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 1.03 Bn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | -4.45 Mn |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | 378.00 Mn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 205.99 Mn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | -453.82 Mn |
| 10 | Legend Biotech | 11.04 Bn | 10.14 Bn | 242.10 Mn | -8.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -8.50 Mn |
| Sep 30, 2025 | -38.46 Mn |
| Jun 30, 2025 | -124.22 Mn |
| Mar 31, 2025 | -97.34 Mn |
| Dec 31, 2024 | 54.80 Mn |
| Sep 30, 2024 | -116.45 Mn |
| Jun 30, 2024 | -17.74 Mn |
| Mar 31, 2024 | -59.78 Mn |
| Dec 31, 2023 | -146.81 Mn |
| Sep 30, 2023 | -684.41 Mn |
| Jun 30, 2023 | 423.07 Mn |
| Mar 31, 2023 | -111.85 Mn |
| Dec 31, 2022 | -135.57 Mn |
| Sep 30, 2022 | 535.35 Mn |
| Jun 30, 2022 | -192.91 Mn |
| Mar 31, 2022 | -31.96 Mn |
| Dec 31, 2021 | -91.95 Mn |
| Sep 30, 2021 | -124.75 Mn |
| Jun 30, 2021 | -172.38 Mn |
| Mar 31, 2021 | -98,685.00 |